Article
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Oncology research and treatment - 1 Jan 2014
Brunner Stefan, von Moos Roger, Mey Ulrich, Camenisch Gross Ulrike, Freyholdt Tobias, Cathomas Richard
Abstract excerpt
BACKGROUND: The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity. Preliminary reports indicate that triplet combination regimens might improve outcome in the RAS/RAF-mutated subgroup. PATIENTS AND METHODS: This retrospective analysis included 25 patients with metastatic colorectal cancer, who received treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.